Wednesday, 6 December 2017

Pharma giant GlaxoSmithKline invests £40m in UK's life sciences sector



Pharma giant GlaxoSmithKline will invest £40m in UK genetic research as part of the government's life sciences sector deal.

 
US drug maker Merck, and diagnostics company QIAGEN last month announced UK investments worth more than £1bn.


Several dozen other companies are expected to announce further deals in the coming weeks.


The government's sector deals are part of its new industrial strategy aimed at boosting UK productivity.


The deals promise partnerships with private sector companies in the construction, artificial intelligence and automotive industries.
The industrial strategy came after the Office for Budget Responsibility announced a sharp downgrade of its forecast for UK economic growth.




BBC        News.